(Q47373403)

English

Effect of rimonabant on weight reduction and cardiovascular risk

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

Effect of rimonabant on weight reduction and cardiovascular risk (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

Bernard Hirschel

1

object named as

Bernard Hirschel

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

366

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

9483

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

369; author reply 369-70

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967019-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967019-5

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 inhibitors--lessons in drug safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967019-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Failing the public health--rofecoxib, Merck, and the FDA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967019-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Coxibs and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967019-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(05)67019-5

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/16054934

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47373403&oldid=2154230191"